SynthesisPharmacoEconomics2005
International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.
Synthesis in PharmacoEconomics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transferability of indirect cost of chronic disease: a systematic review and meta-analysis.PharmacoEconomics · 2013Pooled it
- Trial
- Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort Followed Up From 2003 to 2016.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries.Rheumatology international · 2015Article
- Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs.Arthritis research & therapy · 2014Article
- Medical costs for Korean patients with rheumatoid arthritis based on the national claims database.Rheumatology international · 2012Article
- Thoughts on health economics in rheumatoid arthritis.Annals of the rheumatic diseases · 2007Review
- Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis.Annals of the rheumatic diseases · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent years have witnessed substantial progress in understanding the cost implications of rheumatoid arthritis (RA). To assess the divergent methodologies and their impact on the resulting cost analyses in RA, we conducted a systematic literature review to summarise the scientific evidence of RA-induced costs. Sixty-five reviews, models or cost analyses on the burden of illness and general costs associated with RA were identified. They covered the US, Canada, Sweden, the UK, The Netherlands, Germany and Finland. Twenty-four cost analyses provided appropriate data about direct and/or indirect costs. Each study was summarised separately. Costs were discounted to 2003 and converted to US dollars. The costs per RA-year ranged from USD 1503 to USD 16,514. However, each study has to be interpreted individually, with consideration given to the study population, indication, age of the study, database used, type of therapy, setting, level of cost differentiation and data derivation. Health technology assessment reports offer sufficient space to adequately describe the composite parts and restrictive elements of different methodological approaches and analyses.
Indexed as
Identifiers
15836006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.